Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elicera Therapeutics ABFRA:8E8 -3.87%40 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates FRA:8E8 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 376 Biotechnology companies, Elicera Therapeutics AB ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Elicera Therapeutics AB's
Operating Income
for the
three
months ended in Mar. 2026 was €-0.48 Mil. Elicera Therapeutics AB's Interest Expense for the
three
months ended in Mar. 2026 was €-0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Elicera Therapeutics AB's Interest Coverage or its related term are showing as below:
FRA:8E8's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025 * Ranked among companies with meaningful Interest Coverage only.
Elicera Therapeutics AB (FRA:8E8) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Elicera Therapeutics AB Interest Coverage Related Terms
Elicera Therapeutics AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Elicera Therapeutics AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:8E8 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Elicera Therapeutics AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicera Therapeutics AB Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Elicera Therapeutics AB's Interest Coverage falls into.
Elicera Therapeutics AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Elicera Therapeutics AB did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Elicera Therapeutics AB (FRA:8E8) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Elicera Therapeutics AB and its competitors. According to the industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 376 companies in the Biotechnology industry.
Is Elicera Therapeutics AB's Interest Coverage too high?
Elicera Therapeutics AB's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Elicera Therapeutics AB ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicera Therapeutics AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 376 companies for Interest Coverage. This places Elicera Therapeutics AB in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Elicera Therapeutics AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicera Therapeutics AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (FRA:8E8) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Elicera Therapeutics AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Elicera Therapeutics AB (FRA:8E8), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
40GF Score
Get the complete analysis for FRA:8E8
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8E8 has been successfully added to your 
